EpiLiquid is working on a technology for early cancer diagnosis, based on the detection of epigenetic biomarkers present in the blood system.

Its goal is to develop a minimally invasive test for patients, which only requires a blood draw. This approach is part of what is known as liquid biopsies and is included in personalized precision medicine.